# ADVANCES IN OPHTHALMIC GEL SYSTEMS FOR ENHANCED DELIVERY: A REVIEW OF FORMULATION STRATEGIES AND THERAPEUTIC EFFICACY

**[1]Jayesh Sandip Sawarkar*, [2]Dr. Jitendra Shinde**

[1]Student, [2]Assistant Professor
[1]Pharmaceutics
[1]PDEA's Shankarrao Ursal College of Pharmaceutical Sciences & Research Center, Kharadi, Pune
[1]jayeshsawarkar26@gmail.com, [2]jitushinde29@gmail.com

**Abstract:**

Ocular drug delivery remains a significant therapeutic challenge due to the eye's complex anatomy and protective physiological mechanisms, such as tear drainage, blinking, and the corneal barrier. Due to their low bioavailability, traditional eye drops need frequent dosage, which frequently leads to poor patient compliance. Hydrogel-based ophthalmic gels have become a viable substitute in recent years, providing better therapeutic effectiveness, controlled drug release, and prolonged ocular residency. These gels can gel in situ after delivery because they are made of biocompatible polymers that react to environmental cues like pH and temperature. Their mucoadhesive properties improve absorption by keeping the medication on the eye surface. Achieving the ideal viscosity, drug stability, sanitation, and restricted drug loading capacity are still obstacles, though. Notwithstanding these obstacles, developments in formulation techniques and polymer research are spurring innovation in this area. Furthermore, the review integrates findings from recent literature to evaluate current advances and limitations in gel-based ocular delivery.

Keywords: Ocular drug delivery, hydrogel-based gels, ophthalmic formulations, controlled release, biocompatible polymers.

## Introduction:

Ocular drug delivery presents a formidable challenge due to the eye's unique anatomical and physiological barriers.[1,2] The corneal epithelium, tear turnover, blinking reflex, and nasolacrimal drainage system collectively limit the residence time and absorption of topically administered drugs, resulting in poor bioavailability.[3,4,5] Traditional ophthalmic formulations, such as eye drops, often deliver less than 5% of the administered dose to the intraocular tissues, necessitating frequent dosing and leading to suboptimal

therapeutic outcomes. This inefficiency underscores the need for advanced drug delivery systems that can enhance ocular bioavailability, provide sustained drug release, and improve patient compliance.[6]

Hydrogels' high water content, biocompatibility, and capacity for regulated drug release have made them attractive candidates for ocular drug delivery in recent years.[7,8,9] When administered, hydrogels may be designed to react to a variety of stimuli, including temperature, pH, and ionic strength, allowing for in situ gelation.[10,11] Long-term retention on the ocular surface is made possible by this characteristic, which lowers the frequency of administration and improves therapeutic efficacy.[12,13] Additionally, hydrogels may be made to hold both hydrophilic and hydrophobic medications, increasing their suitability for a variety of eye disorders.[14]

Despite these benefits, there are a number of obstacles in the way of the development of hydrogel-based ocular drug delivery systems. Crucial factors include preserving sterility, attaining the appropriate rheological characteristics for patient comfort, and guaranteeing the stability of the medication inside the hydrogel matrix.[15] The effective transfer of these technologies from laboratory to clinical practice also depends on regulatory compliance and the scalability of manufacturing processes. A multidisciplinary strategy that incorporates knowledge from clinical ophthalmology, pharmaceutical technology, and polymer science is needed to address these issues. [16]

One important risk factor for the development of primary open-angle glaucoma (POAG) is ocular hypertension (OHT), which is defined by increased intraocular pressure (IOP) without discernible glaucomatous damage.[17,18,19] OHT and glaucoma are becoming more common worldwide, which presents a serious public health concern since they can cause permanent vision loss. Preventing the development of glaucomatous optic neuropathy requires effective IOP control.[20,21]

In order to overcome these drawbacks, research on ocular drug delivery systems has shifted its attention to creating innovative formulations that can improve corneal penetration, extend the drug's residence time on the ocular surface, and offer controlled or sustained release. Ophthalmic gels have become viable substitutes for conventional aqueous eye drops in this regard.[22,23] The mucoadhesive qualities of ophthalmic gels, which are usually semi-solid systems made of hydrophilic polymers, enable them to stay in touch with the ocular surface for extended periods of time.[24,25] By increasing the active ingredients bioavailability and perhaps lowering the frequency of delivery, this enhances patient adherence and therapeutic results.[26]

This review offers a critical analysis of contemporary results, the limits of present methodologies, and avenues for further investigation. The objective of this study with this comprehensive investigation is to add to the expanding body of information on enhanced ocular medication delivery systems and help the development of better therapeutics for people suffering from ocular hypertension and associated illnesses.

**Advantages:**

1. **Extended Ocular Residence Time:** Because hydrogels may stick to the surface of the eye, the medication has more time to reach the tissues of the eyes. Improved medication absorption and therapeutic effectiveness may result from this extended residence period. [7,27,28]
2. **Controlled and Sustained Drug Release:** Drugs may be released from hydrogel systems at a regulated pace, which lowers the need for frequent doses and preserves steady therapeutic levels. [29]
3. **Comfort & Biocompatibility:** A lot of hydrogels are made of biocompatible substances that are kind to the tissues of the eyes, reducing irritation and improving patient comfort. [30,31]
4. **Versatility in Drug Loading:** By adding the right modifications or carriers, hydrogels may hold a range of medications, including both hydrophilic and hydrophobic compounds. [32]
5. **Stimulus-Responsive Behavior:** Certain hydrogels have the ability to react to environmental stimuli, such as pH and temperature, enabling in situ gelation after injection. This makes application easier and improves drug retention. [33]

**Disadvantages:**

1. **Formulation Complexity:** In order to attain desired qualities, hydrogel systems must be developed through careful polymer selection, optimization, and crosslinking techniques, all of which can be technically difficult.[15]
2. **Concerns about Stability:** Hydrogels may be susceptible to environmental factors, which might result in problems like water ejection (syneresis), deterioration, or gradual changes in viscosity.[34]
3. **Sterilization Challenges:** Because some sterilization techniques may change the hydrogel's structure or the drug's effectiveness, it can be challenging to maintain sterility without sacrificing the hydrogel's integrity or the drug's activity. [35]
4. **Limited Drug Loading Capacity:** There may be constraints on the amount of drug that can be loaded into a hydrogel, particularly for drugs requiring higher doses, which could limit therapeutic effectiveness. [36]
5. **Probability of Blurred vision:** Because hydrogels are more viscous, they may occasionally temporarily impair eyesight when applied, which might have an impact on patient compliance. [37]

**Classification of Ophthalmic Gels:**

| S. No. | Classification | Description |
|---|---|---|
| **1** | **Composition** | |
| | Hydrogel-based | Contain hydrophilic polymers for moisture and effective drug delivery. |
| | Lipogel-based | Contain lipid-based excipients for drugs requiring lipid absorption. |
| **2** | **Viscosity** | |
| | Low Viscosity | Easier to instill, spreads quickly, and has short retention time. |
| | High Viscosity | Provides longer retention time on the ocular surface. |
| **3** | **Therapeutic Use** | |
| | Anti-inflammatory | For treating inflammation (e.g., corticosteroids, NSAIDs). |
| | Antibiotic | For bacterial infections (e.g., ciprofloxacin, ofloxacin). |
| | Lubricating | For dry eye treatment (e.g., carboxymethylcellulose). |
| | Antiglaucoma | For reducing intraocular pressure (e.g., timolol, latanoprost). |
| **4** | **Mechanism of Action** | |
| | Mucoadhesive | Adheres to mucous membranes, prolonging drug contact time. |
| | Non-mucoadhesive | No strong adhesion, ideal for quick action drugs. |
| **5** | **Release Mechanism** | |
| | Controlled Release | Releases drug over time for sustained effect. |
| | Immediate Release | Releases drug quickly for fast therapeutic action. |

| | | |
|---|---|---|
| **6** | **Preparation Method** | |
| | Cold-formed | Prepared by dissolving polymer in cold water. |
| | Heat-formed | Prepared by heating ingredients before forming the gel. |
| **7** | **pH Sensitivity** | |
| | pH-sensitive | Changes viscosity based on pH, useful for targeted delivery in varying pH environments. |

**The preparation of ophthalmic gels:**

Ophthalmic gels are meticulously formulated to guarantee maximum medication administration, stability, and patient comfort. These gels are intended to improve ocular bioavailability by increasing the drug's residence duration on the eye surface. The following is an overview of the generally used processes in the manufacturing of ophthalmic gels:

**1. Selection of Polymers and Preparation of Solutions**

The basis of ophthalmic gels is the choice of suitable polymers, which dictate the gel's mucoadhesive qualities, viscosity, and physiological stimulus reactivity. The Common polymers include:

- **Carbopol 940:** A pH-sensitive polymer that imitates the ocular environment by changing from a sol to a gel when the pH rises.[38]
- **Sodium Alginate:** Sodium alginate is a common ion-activated polymer found in tear fluid that gels when divalent cations like calcium are present.[39]
- **Poloxamer 407:** This thermosensitive polymer gels at ocular surface temperatures and stays liquid at ambient temperature.[40]
- **Hydroxypropyl Methylcellulose (HPMC):** In addition to other gelling polymers, hydroxypropyl methylcellulose (HPMC) is a mucoadhesive and viscosity booster.[39]

**2. Incorporation of Drugs**

The active pharmaceutical ingredient (API) is added once the polymer solution is clear and uniform. To improve solubility, the API may need solubilizing agents such cyclodextrins, or it should be soluble in the medium. Until the medication is evenly distributed, the mixture is agitated.

---

**3. Adjustment of Physiological Parameters**

To ensure compatibility with the ocular environment and patient comfort, the following parameters are adjusted.

- **pH**: Adjusted to match the physiological pH of tears (~7.4) using buffering agents, ensuring minimal irritation upon administration.[41]
- **Osmolarity**: Tuned to be isotonic with tear fluid to prevent osmotic stress on ocular tissues.[42]
- **Viscosity**: Optimized to balance between sufficient residence time and ease of application.[43]

---

**4. Sterilization**

Sterility is paramount for ophthalmic preparations to prevent infections. The formulated gels are sterilized using methods such as:

- **Autoclaving**: Subjecting the formulation to moist heat at 121°C for 15 minutes.[39]
- **Filtration**: Passing the solution through a 0.22 µm membrane filter, especially suitable for heat-sensitive components.[44]

---

**5. Storage and Packaging**

The gels are aseptically put into appropriate ophthalmic containers after sterilization, guaranteeing contamination prevention. In order to protect the integrity of thermosensitive formulations, storage conditions are kept in accordance with stability criteria, frequently under refrigeration.[45]

To guarantee that the finished product is safe, efficient, and patient-friendly, every stage of the ophthalmic gel production process is essential. The effectiveness of these ocular formulations is continuously improved by developments in drug delivery technologies and polymer science.

**Conclusion:**

Hydrogel-based ophthalmic gels represent a pivotal advancement in ocular drug delivery, effectively addressing many limitations associated with conventional eye drop formulations. These gels have special qualities including great biocompatibility, prolonged and regulated drug release, and reactivity to physiological cues. Their mucoadhesive properties increase eye surface contact, which improves absorption and lowers administration frequency, eventually resulting in better therapeutic results and patient adherence.

There are still a number of formulation and translational issues despite their potential. Important issues still include obtaining sterility without sacrificing drug integrity, guaranteeing proper rheological behavior for patient comfort, and preserving drug stability inside the hydrogel matrix. Additionally, cautious formulation design is necessary due to drug loading capacity constraints and the possibility of transient visual disruption.

However, hydrogel-based systems are still being improved by continuous research that combines concepts from clinical ophthalmology, pharmaceutical technology, and polymer chemistry. In order to create reliable, scalable, and legally compliant solutions that work well in clinical settings, these efforts are essential. Such sophisticated compositions have a lot of promise, especially for treating ocular hypertension and avoiding glaucoma. In order to further improve these systems for broad clinical usage, future research should concentrate on resolving current issues and investigating new polymers and medication combinations.

**References:**

1. Chandel, A., & Kandav, G. (2024). Insights into ocular therapeutics: a comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery. Journal of Drug Delivery Science and Technology, 105785.
2. Cholkar, K., Dasari, S. R., Pal, D., & Mitra, A. K. (2013). Eye: anatomy, physiology and barriers to drug delivery. In Ocular transporters and receptors (pp. 1-36). Woodhead publishing.
3. Ahmed, S., Amin, M. M., & Sayed, S. (2023). Ocular drug delivery: a comprehensive review. AAPS PharmSciTech, 24(2), 66.
4. Lanier, O. L., Manfre, M. G., Bailey, C., Liu, Z., Sparks, Z., Kulkarni, S., & Chauhan, A. (2021). Review of approaches for increasing ophthalmic bioavailability for eye drop formulations. Aaps Pharmscitech, 22, 1-16.
5. Akhter, M. H., Ahmad, I., Alshahrani, M. Y., Al-Harbi, A. I., Khalilullah, H., Afzal, O., & Karim, S. (2022). Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels, 8(2), 82.
6. Patel, P. B., Shastri, D., Shelat, P., & Shukla, A. (2010). Ophthalmic drug delivery system: challenges and approaches. Systematic Reviews in Pharmacy, 1(2), 113.
7. Fang, G., Yang, X., Wang, Q., Zhang, A., & Tang, B. (2021). Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases. Materials Science and Engineering: C, 127, 112212.

8. Qiu, Y., & Park, K. (2001). Environment-sensitive hydrogels for drug delivery. Advanced drug delivery reviews, 53(3), 321-339.
9. Ribeiro, A. M., Figueiras, A., & Veiga, F. (2015). Improvements in topical ocular drug delivery systems: hydrogels and contact lenses. Journal of Pharmacy and Pharmaceutical Sciences, 18(5), 683.
10. He, C., Kim, S. W., & Lee, D. S. (2008). In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. Journal of controlled release, 127(3), 189-207.
11. Ruel-Gariepy, E., & Leroux, J. C. (2004). In situ-forming hydrogels—review of temperature-sensitive systems. European Journal of Pharmaceutics and Biopharmaceutics, 58(2), 409-426.
12. Shatz, W., Aaronson, J., Yohe, S., Kelley, R. F., & Kalia, Y. N. (2019). Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases. Expert opinion on drug delivery, 16(1), 43-57.
13. Belamkar, A., Harris, A., Zukerman, R., Siesky, B., Oddone, F., Verticchio Vercellin, A., & Ciulla, T. A. (2022). Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications. Annals of Medicine, 54(1), 343-358.
14. Hu, X., Hao, L., Wang, H., Yang, X., Zhang, G., Wang, G., & Zhang, X. (2011). Hydrogel contact lens for extended delivery of ophthalmic drugs. International Journal of Polymer Science, 2011(1), 814163.
15. Cooper, R. C., & Yang, H. (2019). Hydrogel-based ocular drug delivery systems: Emerging fabrication strategies, applications, and bench-to-bedside manufacturing considerations. Journal of controlled release, 306, 29-39.
16. Liu, B., & Chen, K. (2024). Advances in hydrogel-based drug delivery systems. Gels, 10(4), 262.
17. Weinreb, R. N., Leung, C. K., Crowston, J. G., Medeiros, F. A., Friedman, D. S., Wiggs, J. L., & Martin, K. R. (2016). Primary open-angle glaucoma. Nature reviews Disease primers, 2(1), 1-19.
18. Landers, J., Goldberg, I., & Graham, S. L. (2002). Analysis of risk factors that may be associated with progression from ocular hypertension to primary open angle glaucoma. Clinical & experimental ophthalmology, 30(4), 242-247.
19. Grzybowski, A., Och, M., Kanclerz, P., Leffler, C., & De Moraes, C. G. (2020). Primary open angle glaucoma and vascular risk factors: a review of population based studies from 1990 to 2019. Journal of clinical medicine, 9(3), 761.
20. Allison, K., Patel, D., & Alabi, O. (2020). Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus, 12(11).
21. Stewart, W. C., Stewart, J. A., & Nelson, L. A. (2011). Ocular surface disease in patients with ocular hypertension and glaucoma. Current eye research, 36(5), 391-398.
22. Swindle, K. E., & Ravi, N. (2007). Recent advances in polymeric vitreous substitutes. Expert Review of Ophthalmology, 2(2), 255-265.

23. Lin, K. T., Wang, A., Nguyen, A. B., Iyer, J., & Tran, S. D. (2021). Recent advances in hydrogels: ophthalmic applications in cell delivery, vitreous substitutes, and ocular adhesives. Biomedicines, 9(9), 1203.
24. Wilson, C. G. (2022). Ophthalmic Formulation.
25. Berillo, D., Zharkinbekov, Z., Kim, Y., Raziyeva, K., Temirkhanova, K., & Saparov, A. (2021). Stimuli-responsive polymers for transdermal, transmucosal and ocular drug delivery. Pharmaceutics, 13(12), 2050.
26. Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023). Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nature Reviews Drug Discovery, 22(5), 387-409.
27. Kushwaha, S. K., Saxena, P., & Rai, A. K. (2012). Stimuli sensitive hydrogels for ophthalmic drug delivery: A review. International journal of pharmaceutical investigation, 2(2), 54.
28. Zignani, M., Tabatabay, C., & Gurny, R. (1995). Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. Advanced drug delivery reviews, 16(1), 51-60.
29. Lin, Z., Gao, W., Hu, H., Ma, K., He, B., Dai, W., ... & Zhang, Q. (2014). Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity. Journal of Controlled Release, 174, 161-170.
30. Aswathy, S. H., Narendrakumar, U., & Manjubala, I. (2020). Commercial hydrogels for biomedical applications. Heliyon, 6(4).
31. Wu, H., Wang, J., Fan, W., Zhong, Q., Xue, R., Li, S., ... & Tao, Y. (2024). Eye of the future: Unlocking the potential utilization of hydrogels in intraocular lenses. Bioengineering & Translational Medicine, 9(5), e10664.
32. Larrañeta, E., Stewart, S., Ervine, M., Al-Kasasbeh, R., & Donnelly, R. F. (2018). Hydrogels for hydrophobic drug delivery. Classification, synthesis and applications. Journal of functional biomaterials, 9(1), 13.
33. Pandey, M., Choudhury, H., binti Abd Aziz, A., Bhattamisra, S. K., Gorain, B., Su, J. S. T., ... & Yip, K. Y. (2021). Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery: Recent progress and contemporary research. Polymers, 13(8), 1340.
34. Chen, M., Wang, W., Fang, J., Guo, P., Liu, X., Li, G., ... & Lei, K. (2023). Environmentally adaptive polysaccharide-based hydrogels and their applications in extreme conditions: A review. International Journal of Biological Macromolecules, 241, 124496.
35. Galante, R., Pinto, T. J., Colaco, R., & Serro, A. P. (2018). Sterilization of hydrogels for biomedical applications: A review. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 106(6), 2472-2492.

36. Torres-Luna, C., Fan, X., Domszy, R., Hu, N., Wang, N. S., & Yang, A. (2020). Hydrogel-based ocular drug delivery systems for hydrophobic drugs. European Journal of Pharmaceutical Sciences, 154, 105503.
37. Al-Shohani, A. D. H. (2017). Hydrogel formulations for ophthalmic delivery (Doctoral dissertation, UCL (University College London)).
38. Sheshala, R., Ming, N. J., Kok, Y. Y., Singh, T. R. R., & Dua, K. (2019). Formulation and characterization of pH induced in situ gels containing sulfacetamide sodium for ocular drug delivery: A combination of Carbopol®/HPMC polymer. Indian Journal of Pharmaceutical Education and Research.
39. Mandal, S., Thimmasetty, M. K., Prabhushankar, G. L., & Geetha, M. S. (2012). Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride. International journal of pharmaceutical investigation, 2(2), 78.
40. Chen, Y., Lee, J. H., Meng, M., Cui, N., Dai, C. Y., Jia, Q., ... & Jiang, H. B. (2021). An overview on thermosensitive oral gel based on poloxamer 407. Materials, 14(16), 4522.
41. Stanciauskaite, M., Marksa, M., Ivanauskas, L., Perminaite, K., & Ramanauskiene, K. (2021). Ophthalmic in situ gels with balsam poplar buds extract: Formulation, rheological characterization, and quality evaluation. Pharmaceutics, 13(7), 953.
42. Dutescu, R. M., Panfil, C., & Schrage, N. (2015). Osmolarity of prevalent eye drops, side effects, and therapeutic approaches. Cornea, 34(5), 560-566.
43. Zhu, H., & Chauhan, A. (2008). Effect of viscosity on tear drainage and ocular residence time. Optometry and Vision Science, 85(8), E715-E725.
44. Wang, Y., Hammes, F., Boon, N., & Egli, T. (2007). Quantification of the filterability of freshwater bacteria through 0.45, 0.22, and 0.1 μm pore size filters and shape-dependent enrichment of filterable bacterial communities. Environmental science & technology, 41(20), 7080-7086.
45. Sandle, T. (2014). Sterile ophthalmic preparations and contamination control. J. GXP Compliance, 18, 1-5.